EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals cut 53% of its workforce and ended a Phase III trial for duravyu after it failed to meet the primary endpoint in a wet age-related macular degeneration study. The company will focus on duravyu's development for diabetic macular oedema, with topline data expected in Q4 2027. EyePoint's stock dropped over 80% following the announcement.
How this was made
The 30-second read
Why it matters
The abrupt termination signals a major setback for the company's pipeline, prompting a sharp sell‑off and raising questions about future cash needs.
Market read
EyePoint's stock plunge reflects the market's reaction to a failed pivotal trial, with potential spill‑over to other ocular‑therapy stocks.
What to watch
EyePoint's cash runway and cost‑saving measures could stabilize the balance sheet despite the setback.
Background
EyePoint Pharmaceuticals (NASDAQ: EYPT) focuses on ocular disease therapies. The LUCIA Phase III trial compared its candidate duravyu to Eylea in wet AMD patients.
Ticker impact
EyePoint announced the termination of its Phase III LUCIA trial after duravyu missed the primary endpoint, causing an 80% stock drop.
likely further downside as investors price in the lost Phase III program.
Clinical‑trial miss is a material catalyst; the stock already fell 80% and no mitigating news was provided.
Market effects
Anti‑VEGF market may see increased focus on existing therapies like Eylea and Vabysmo as a competitor stalls.
US biotech sector could face short‑term pressure from the news.
Limited to ophthalmology and biotech investors; no broad market effect.
Counterpoint
Duravyu may still succeed in diabetic macular oedema, offering a potential rebound if Phase II data holds.
Key entities
- companyEyePoint Pharmaceuticals
US‑listed biotech developing duravyu.
- competitorBayer/Regeneron (Eylea)
Current standard of care in wet AMD.